Back
Download our official app here to personalize your agenda and set up session reminders.

Forging Therapeutics

Thu Oct 26, 2017
11:00 AM - 11:20 AM
Main Ballroom A/B/C

Description

At Forge Therapeutics, we are developing medicines targeting metal-dependent enzymes found in nature.  Over 30% of known enzymes are metalloenzymes covering all major enzymes classes: oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases.  Metal ions, including magnesium, zinc, iron, manganese, calcium, cobalt, and copper are the essential ingredient in these metalloenzymes.  At Forge, we are the blacksmiths of modern medicine, providing the tools to address any metalloenzyme challenge.

Forge’s lead effort is focused on LpxC, a zinc metalloenzyme found only in Gram-negative bacteria and which is essential for bacteria to grow. Forge has a strategic alliance with leading drug discovery alliance and development partnership company Evotec AG and has been awarded multiple government awards including CARB-X. In addition, Forge has amassed a rich intellectual property estate on metalloprotein inhibitors to protect its BLACKSMITH platform and pipeline including technology licensed from UCSD. For further information, please visit the company’s website www.ForgeTherapeutics.com and follow us on Twitter @ForgeThera.


Speaker:

 
Zachary Zimmerman, Ph.D.
CEO, Forge Therapeutics, Inc.

Add to my schedule

Create your personal schedule through the official app, Whova!

Get Started